Kindred Biosciences Stock Forecast, Price & News

+0.04 (+0.44 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume307,922 shs
Average Volume861,220 shs
Market Capitalization$414.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Kindred Biosciences logo

About Kindred Biosciences

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.56 out of 5 stars

Medical Sector

887th out of 2,216 stocks

Pharmaceutical Preparations Industry

430th out of 869 stocks

Analyst Opinion: 2.1Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

Is Kindred Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Kindred Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View analyst ratings for Kindred Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Kindred Biosciences?

Wall Street analysts have given Kindred Biosciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a drop in short interest in July. As of July 15th, there was short interest totaling 1,030,000 shares, a drop of 15.6% from the June 30th total of 1,220,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the short-interest ratio is presently 0.8 days. Currently, 2.8% of the company's stock are sold short.
View Kindred Biosciences' Short Interest

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Kindred Biosciences

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings data on Monday, May, 10th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.24). The biopharmaceutical company had revenue of $2.40 million for the quarter, compared to analyst estimates of $4.60 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 8.50% and a negative net margin of 19.96%.
View Kindred Biosciences' earnings history

How has Kindred Biosciences' stock price been impacted by Coronavirus?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KIN shares have increased by 12.7% and is now trading at $9.12.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KIN?

5 brokerages have issued 12 month price objectives for Kindred Biosciences' stock. Their forecasts range from $9.25 to $15.25. On average, they anticipate Kindred Biosciences' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 17.9% from the stock's current price.
View analysts' price targets for Kindred Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 54, Pay $820.62k)
  • Ms. Denise M. Bevers, Co-Founder & Director (Age 54, Pay $1.44M)
  • Ms. Wendy K. Wee, CFO & Sec. (Age 68, Pay $405.44k)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 61, Pay $410.87k)
  • Dr. Ernest Mario, Advisor (Age 82)
  • Ms. Katja Buhrer, Chief of Staff, VP of Corp. Devel. & Investor Relations

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Harvest Management LLC (0.17%). Company insiders that own Kindred Biosciences stock include Denise Bevers, Park West Asset Management Llc and Richard Chin.
View institutional ownership trends for Kindred Biosciences

Which major investors are buying Kindred Biosciences stock?

KIN stock was purchased by a variety of institutional investors in the last quarter, including Harvest Management LLC.
View insider buying and selling activity for Kindred Biosciences
or or view top insider-buying stocks.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $9.12.

How much money does Kindred Biosciences make?

Kindred Biosciences has a market capitalization of $414.61 million and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Kindred Biosciences have?

Kindred Biosciences employs 63 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is

Where are Kindred Biosciences' headquarters?

Kindred Biosciences is headquartered at 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.